The Federal Trade Commission and seven U.S. states are seeking to hold Martin Shkreli in contempt for allegedly influencing biopharma stocks despite being banned from the industry. The former hedge-fund manager rose to fame a decade ago by acquiring the rights to Daraprim, a drug used to treat toxoplasmosis, a rare parasitic infection primarily affecting immunocompromised patients. He then raised the price of the medication from $17.50 to $750 per tablet. This practice sparked widespread debate over soaring drug prices in the United States.
Source: Read the original article
Disclaimer: this content is for information purposes only and is not financial advice. Cryptocurrencies are highly volatile: you may lose all of your capital. Always do your own research. Legal notice
